An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies

Official Title

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

Summary:

The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies

Trial Description

Primary Outcome:

  • Incidence of dose limiting toxicity (DLT)
  • Incidence of serious adverse events (SAEs)
  • Incidence of adverse events (AEs)
  • Overall Survival (OS)
  • Progression Free Survival (PFS)
Secondary Outcome:
  • Incidence of AEs
  • Incidence of SAEs
  • Incidence of laboratory abnormalities
  • Progression Free Survival (PFS)
  • Overall Survival
  • Progression Free Survival
  • Overall Survival (OS)
  • Overall Survival

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society